pharma news today glp-1 obesity drug updates Targeted Peptide Weight Loss Drugs Market Size to Reach USD 193.44 Billion by 2034 Market Overview: GLP-1 Agonists and

Dysmotility refers to abnormal motion through the gastrointestinal tract, either too fast, too slow or in the wrong direction

Citation: Gorouhi, F., & Maibach, H

People with impaired FMO3 activity either due to genetic variants known to cause trimethylaminuria or due to liver disease have reduced ability to clear TMA

Effect of vitamin E and selenium nanoparticles on post-thaw variables and oxidative status of rooster semen

Normal growth and development in the absence of hepatic insulin-like growth factor I

Body odor is produced when skin-resident bacteria metabolize sweat compounds into volatile organic compounds (VOCs) such as thioalcohols, volatile fatty acids, and ammonia